TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27029034

Group type: EXPERIMENTAL
Intervention: Sunitinib (50mg) therapy for 3 cycles
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated biopsy samples
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nephrectomy samples after sunitinib treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Renal artery ligation
Number of subjects: 14
Study: 27029228

Group type: EXPERIMENTAL
Intervention: Bendamustine (90 mg/m² on days 1 and 2) plus Rituximab (375 mg/m² on day 1), every 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab (as described above)
Number of subjects: 60
Study: 27029399

Group type: EXPERIMENTAL
Intervention: Prehospital GIS data implementation in the ED
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Nurses' perceptions regarding patient reception, workflow, and resource utilization
Number of subjects: 599

Group type: COMPARATOR
Intervention: Comparison with control period (no GIS data)
Number of subjects: 599
Study: 27029636

Group type: EXPERIMENTAL
Intervention: Ethosuximide and Valproic Acid
Number of subjects: 445

Group type: COMPARATOR
Intervention: NHANES controls
Number of subjects: 445
Study: 27029940

Group type: EXPERIMENTAL
Intervention: Low-phytic acid beans (lpa)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans (BBs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control beans (CBs)
Number of subjects: 25
Study: 27030066

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Enoxaparin and vitamin K antagonist (1.0 mg/kg twice daily and warfarin or acenocoumarol; INR 2.0-3.0)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 655

Group type: COMPARATOR
Intervention: Enoxaparin and vitamin K antagonist
Number of subjects: 655
Study: 27030277

Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (1.25 mg/0.05 mL)
Number of subjects: 30
Study: 27030279

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 1695
Study: 27030531

Group type: EXPERIMENTAL
Intervention: Diets containing dietary pulses (median intake of 132 g/d or ∼1 serving/d)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Matched negative-energy-balance diets
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Neutral-energy-balance diets
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Diets containing dietary pulses
Number of subjects: 940
Study: 27030536

Group type: EXPERIMENTAL
Intervention: Milk samples from healthy lactating women
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Urine samples from healthy lactating women
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of urine concentrations between subjects consuming organic vs conventionally grown foods
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison of urine concentrations between women living on or near a farm/ranch vs urban/suburban areas
Number of subjects: 41
Study: 27031231

Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (ASAQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ASAQ and AL
Number of subjects: 0
Study: 27032057

Group type: EXPERIMENTAL
Intervention: Cu IUD
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Oral LNG
Number of subjects: 548
Study: 27032301

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus neoadjuvant chemotherapy (intravenous fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m², and bevacizumab 15 mg/kg during cycles 1-4; docetaxel 100 mg/m² and bevacizumab during cycles 5-8)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bevacizumab (adjuvant)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (without bevacizumab)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 100
Study: 27033025

Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27033062

Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 66
Study: 27033711

Group type: EXPERIMENTAL
Intervention: Aerosolised colistin (AS) - 4 million units by nebulisation three times per 24 hours
Number of subjects: 149
Study: 27033958

Group type: EXPERIMENTAL
Intervention: Intravesical administration of hyaluronic acid and chondroitin sulfate (HA+CS)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry)
Number of subjects: 276
Study: 27034426

Group type: EXPERIMENTAL
Intervention: Consistent condom use in the last month
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Factors associated with lower odds of consistent condom use
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Factors associated with higher likelihood of consistent condom use
Number of subjects: 175
Study: 27034453

Group type: EXPERIMENTAL
Intervention: HIV-1 infection with MetS
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: HIV-1 infection without MetS
Number of subjects: 301

Group type: COMPARATOR
Intervention: General population (Framingham cohort)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Overall HIV-1 infection
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: MetS
Number of subjects: 301
Study: 27035377

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Anemia group
Number of subjects: 455

Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 455
Study: 27035632

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) score ≥ 6 at admission
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS) score ≥ 6 at 6 months
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Higher GDS score at 6 months
Number of subjects: 306
Study: 27036160

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (3 mg/m² IV on day 1), all-trans retinoic acid (45 mg/m² orally on days 4-6 and 15 mg/m² orally on days 7-28), high-dose cytarabine (3 g/m²/12 h IV on days 1-3), mitoxantrone (12 mg/m² IV on days 2-3)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patients responding to salvage therapy and undergoing allogeneic hematopoietic cell transplantation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fms-like tyrosine kinase internal tandem duplication positive AML
Number of subjects: 93
Study: 27036163

Group type: EXPERIMENTAL
Intervention: Multimodal intervention integrated into clinical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 27036994

Group type: EXPERIMENTAL
Intervention: Prevalence of viraemia
Number of subjects: 26503

Group type: EXPERIMENTAL
Intervention: Aware viral load
Number of subjects: 26503

Group type: EXPERIMENTAL
Intervention: Population viral load
Number of subjects: 26503

Group type: EXPERIMENTAL
Intervention: Population ART coverage
Number of subjects: 26503

Group type: EXPERIMENTAL
Intervention: In-care viral load
Number of subjects: 26503
Study: 27037650

Group type: EXPERIMENTAL
Intervention: Leuven Immunomodulatory Protocol (LIP)
Number of subjects: 13
Study: 27037664

Group type: EXPERIMENTAL
Intervention: Healthy plaque stimulation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diseased plaque stimulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Whole blood from healthy siblings
Number of subjects: 33
Study: 27039126

Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 0
Study: 27039387

Group type: EXPERIMENTAL
Intervention: Ixazomib 3 mg weekly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg weekly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ixazomib 5.5 mg (maximum tolerated dose)
Number of subjects: 44
Study: 27039928

Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: PAP withdrawal
Number of subjects: 84
Study: 27039986

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g TID
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g BID
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 60
Study: 27040099

Group type: EXPERIMENTAL
Intervention: Nonradiation EUS-based ERCP
Number of subjects: 31
Study: 27040320

Group type: EXPERIMENTAL
Intervention: Pralatrexate (10 to 30 mg/m²) + Bortezomib (1.3 mg/m²)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pralatrexate + Bortezomib
Number of subjects: 11
Study: 27041409

Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) in a Phase III clinical trial
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Worst pain numeric rating scale
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Measurement Information System physical functioning items
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Universities Osteoarthritis Index
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Worst stiffness numeric rating scale developed for TGCT
Number of subjects: 22
Study: 27042048

Group type: EXPERIMENTAL
Intervention: Phenotyping patients with COPD in a real-life setting
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Analysis of differences in symptoms and therapeutic behavior
Number of subjects: 84
Study: 27042163

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily (first dose 110 mg 1-4 h after surgery)
Number of subjects: 5292
Study: 27042281

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 22
Study: 27042285

Group type: EXPERIMENTAL
Intervention: Copy number variations (CNVs) affecting PARK2 gene
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: ASD cases with exonic duplication of PARK2
Number of subjects: 335

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 335
Study: 27042312

Group type: EXPERIMENTAL
Intervention: Maximal strength training (85-90% of 1 repetition maximum (1RM)) 3 times a week for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional clinical activities
Number of subjects: 24
Study: 27042326

Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (cf-PWV) measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Augmentation index (AIx@HR75) measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Central pulse pressure (CPP) measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intra-class correlation coefficients (ICCs) for reproducibility
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Standard vs direct method for distance measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patient acceptance and comfort survey
Number of subjects: 15
Study: 27042336

Group type: EXPERIMENTAL
Intervention: Tender joints
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Synovitis (clinical assessment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Synovitis (PDUS assessment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tender joints with synovitis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Non-tender joints with no synovitis
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Persistence of tender joints
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Persistence of synovitis
Number of subjects: 59
Study: 27042677

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27042931

Group type: EXPERIMENTAL
Intervention: Surveillance after 5 and 10 years
Number of subjects: 27450

Group type: COMPARATOR
Intervention: Surveillance after 10 years only
Number of subjects: 27450

Group type: EXPERIMENTAL
Intervention: Surveillance after 3, 5, and 10 years
Number of subjects: 27450

Group type: COMPARATOR
Intervention: Surveillance after 5 and 10 years only
Number of subjects: 27450

Group type: EXPERIMENTAL
Intervention: Surveillance after 5 and 10 years for patients with serrated polyps ≥10mm or serrated polyps ≥5mm proximal to the splenic flexure
Number of subjects: 27450
Study: 27043883

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Transplant-free survival (TFS)
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Posttransplantation survival
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Red blood cell infusions
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Plasma infusions
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 2070

Group type: COMPARATOR
Intervention: Vasopressors
Number of subjects: 2070
Study: 27044252

Group type: EXPERIMENTAL
Intervention: French cohort
Number of subjects: 120

Group type: COMPARATOR
Intervention: Australian cohort
Number of subjects: 120
Study: 27044310

Group type: EXPERIMENTAL
Intervention: Telerehabilitation technology with step counter (Fitbit Zip) monitoring for 12 months.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Telerehabilitation at a call center.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Younger patients and those who used the pedometer longer walked significantly more steps (P=.01 and P=.04 respectively).
Number of subjects: 64

Group type: COMPARATOR
Intervention: Three rehabilitation settings (call center, community health care center, hospital).
Number of subjects: 64
Study: 27044576

Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol 5/5 µg with exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol 5/5 µg without exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tiotropium 5 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 27044936

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4891

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 4891

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 4891

Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS
Number of subjects: 4891

Group type: COMPARATOR
Intervention: Tamoxifen plus OFS
Number of subjects: 4891
Study: 27044938

Group type: EXPERIMENTAL
Intervention: LY2606368 at 40 mg/m(2) (schedule 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LY2606368 at 105 mg/m(2) (schedule 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LY2606368
Number of subjects: 45
Study: 27045102

Group type: EXPERIMENTAL
Intervention: Biomarker-selected clinical trials (ATTACC-companion clinical trials)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Nonbiomarker selected clinical trials
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Early molecular screening for ATTACC-companion clinical trials
Number of subjects: 484
Study: 27045164

Group type: EXPERIMENTAL
Intervention: Bosutinib therapy in AP CML patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Bosutinib therapy in BP CML patients
Number of subjects: 140
Study: 27045564

Group type: EXPERIMENTAL
Intervention: Preprocedural analgesia
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Continuous analgesia
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Successful venipuncture in one attempt
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: High pain scores
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Lack of preprocedural analgesia
Number of subjects: 495
Study: 27045862

Group type: EXPERIMENTAL
Intervention: Serum betatrophin levels in patients with NAFLD
Number of subjects: 164

Group type: COMPARATOR
Intervention: Serum betatrophin levels in controls
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Correlation of circulating betatrophin with obesity and glycemic indices
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Insulin resistance index effect on betatrophin levels
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Hepatic expression of betatrophin in mice with NAFLD
Number of subjects: 164
Study: 27046364

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB or LAGB)
Number of subjects: 2221
Study: 27047630

Group type: EXPERIMENTAL
Intervention: Micro-focused ultrasound with visualization with vertical vectoring treatment
Number of subjects: 20
Study: 27048632

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 303
Study: 27048707

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 27048835

Group type: EXPERIMENTAL
Intervention: Probiotic combination of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 (BB12)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Control chewing tablet
Number of subjects: 983
Study: 27048911

Group type: EXPERIMENTAL
Intervention: Lurasidone 40-120 mg once daily
Number of subjects: 251
Study: 27049236

Group type: EXPERIMENTAL
Intervention: TGFβ isoforms (TGFβ1 and TGFβ3) stimulation in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COL4A1 expression in obese subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COL4A1 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGFβ isoforms (TGFβ1 and TGFβ3) exposure
Number of subjects: 0
Study: 27049457

Group type: EXPERIMENTAL
Intervention: CUDC-907 once-daily (MTD 60 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CUDC-907 twice-weekly (MTD 150 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CUDC-907 three-times-weekly (MTD 150 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CUDC-907 5/2 dosing schedule (MTD 60 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: CUDC-907 (overall)
Number of subjects: 44
Study: 27049487

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg q.d. (12 or 24 weeks) with PegIFN/RBV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg q.d. (12 weeks) with PegIFN/RBV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with PegIFN/RBV
Number of subjects: 0
Study: 27049694

Group type: EXPERIMENTAL
Intervention: Women with excess adiposity (BMI ≥25.0 kg/m2)
Number of subjects: 2619

Group type: EXPERIMENTAL
Intervention: Women with anaemia (Hb <120 g/l)
Number of subjects: 2619

Group type: EXPERIMENTAL
Intervention: Women with both overweight and anaemia
Number of subjects: 2619

Group type: EXPERIMENTAL
Intervention: Gender inequalities in overweight adjusted for covariates
Number of subjects: 2619

Group type: EXPERIMENTAL
Intervention: Gender inequality in anaemia or overweight and anaemia
Number of subjects: 2619
Study: 27050437

Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) defined as Apnea-Hypopnea Index (AHI) ≥10
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: OSA severity defined according to AHI quartile
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: OSA severity
Number of subjects: 123
Study: 27050823

Group type: EXPERIMENTAL
Intervention: Weighed Blood Loss (WBL)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Laboratory-based methods of PPH diagnosis
Number of subjects: 1140
Study: 27051260

Group type: EXPERIMENTAL
Intervention: Watch PAT-100 portable monitoring device for full-night unattended polysomnography
Number of subjects: 19
Study: 27052654

Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel (MBC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel (LABC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel + pertuzumab (LABC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel ± pertuzumab
Number of subjects: 98
Study: 27052658

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once a day) plus prednisone (5 mg twice a day)
Number of subjects: 30
Study: 27053275

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (AP)
Number of subjects: 200
Study: 27053291

Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: D-dimer testing with additional factors (sex, age, Katz ADL)
Number of subjects: 524
Study: 27053381

Group type: COMPARATOR
Intervention: Indian neonates
Number of subjects: 333

Group type: COMPARATOR
Intervention: Malay neonates
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Chinese neonates
Number of subjects: 333
Study: 27053961

Group type: EXPERIMENTAL
Intervention: Behavioral evaluation of cognitive function, adaptive function, autism symptoms, and problem behaviors.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Behavioral evaluation of aggressive behavior.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Assessment of autism diagnostic instruments.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation of serum and CSF 7-DHC and 8-DHC with functioning.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Developmental milestones evaluation.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CSF cholesterol correlation with cognitive or adaptive functioning.
Number of subjects: 33
Study: 27054029

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) involving 3 cycles of 5 min of lower limb occlusion with a pneumatic tourniquet inflated to 200 mmHg alternating with 5 min of reperfusion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control involving the cuff placed on the thigh without inflation.
Number of subjects: 0
Study: 27054272

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Other AED
Number of subjects: 1004
Study: 27054297

Group type: EXPERIMENTAL
Intervention: Standard oral glucose tolerance test (OGTT)
Number of subjects: 962
Study: 27054341

Group type: EXPERIMENTAL
Intervention: Small-group counseling intervention (7 sessions, 2 hours each)
Number of subjects: 0